Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2008

View Archived Issues

Further clinical study of MK-7009 to follow evaluation in healthy volunteers

Anti-HCV activity of R-7128 seen in different races/ethnicities

Takeda updates key milestones of first half of 2008

Novel dual CB1/CB2 receptor agonist efficacious in experimental pain models

Helsinn Healthcare and Zealand Pharma partner for ZP-1846

ProStrakan grants license to Bayer Schering for Tostran testosterone treatment

Prana provides update on research and development programs

GFT-505 shows beneficial effect on plasma lipids

Novel agents for cardiovascular disorders disclosed in recent CTG Pharma patent

Streptococcal endopeptidase IdeS prevents experimental glomerulonephritis

Recent patents describe new treatment options for thrombotic disorders

ONO-1301MS may improve tubulointerstitial injury in chronic kidney disease

Novel antiinflammatory agents jointly claimed by Boehringer Ingelheim and Biolipox

Phase II chronic plaque psoriasis study with ALT-2074 currently enrolling patients

Positive results reported for novel HDAC inhibitor in experimental Huntington's disease in mice

Ark files MAA with EMEA for Cerepro for malignant glioma

FDA accepts Cell Therapeutics' Zevalin sBLA and grants priority review

FDA approves Duramed's synthetic conjugated estrogens-A cream

Quintiles acquires Targeted Molecular Diagnostics

Lexicon files IND with the FDA for LX-4211 as a potential treatment for diabetes

Paladin and GSK sign 3-year distribution agreement for Dexedrine for ADHD

TorreyPines reports results from study of NGX-426 in capsaicin-induced pain

ANA-598 receives FDA fast track designation for chronic hepatitis C infection

FDA grants orphan drug designation to pralatrexate for follicular lymphoma

ViroPharma submits sBLA for Cinryze for hereditary angioedema

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...